Search Details

Word: tb (lookup in dictionary) (lookup stats)
Dates: during 2010-2019
Sort By: most recent first (reverse)


Usage:

After a long period of decline, TB incidence has risen dramatically since the 1980s, despite the improvement of sanitary conditions, the development of anti-TB drugs in the 1950s, and the introduction of the World Health Organization’s directly-observed treatment short-course program for more effective treatment. In 1993, the WHO declared TB a global-health emergency, setting ambitious goals which it later conceded could not be met by 2003 or possibly even 2015. That is to say, the consequences from the years of inadequate treatment and low attention to disease control in resource-poor regions have...

Author: By Thomas J. Hwang | Title: To Be or not TB | 4/28/2010 | See Source »

...logistical and financial hurdles associated with paying for and completing treatment, however, virtually guarantee noncompliance and relapse. Second, in a cascade effect, noncompliance selects for drug-resistant strains of the mutated pathogen, precipitating the rise of multi-drug resistant and extremely drug-resistant tuberculosis. Treatment for drug-resistant TB with second-line drugs is astronomically more expensive, more time-intensive, and associated with more toxic side effects. Third, the rise of TB and human immunodeficiency virus coinfection means TB is leading cause of death among HIV-positive patients: In Africa, HIV is the single most important factor contributing...

Author: By Thomas J. Hwang | Title: To Be or not TB | 4/28/2010 | See Source »

...tepid support from the pharmaceutical industry. Thanks largely to years of advocacy and the establishment of innovative public-private partnerships spanning the two sectors, new drugs and new models of clinical development are finally in the pipeline. Instead of developing new drugs one-by-one, the Critical Path to TB Regimens Initiative would bring together drug developers, under a “patients-first” commitment, to test their compounds together as an entirely new four-drug combination—a process that would take six, rather than 24, years...

Author: By Thomas J. Hwang | Title: To Be or not TB | 4/28/2010 | See Source »

...therapeutic regimens represent, however, only half the solution. Without commensurate scale-up of community-based treatment programs—the “social” dimension of treatment—or reform of inefficient drug delivery mechanisms in developing countries, TB treatment will remain inaccessible, ineffective, and ultimately futile. To finally turn the clock back on the spread of TB and its even more dangerous resistant strains, we need a concerted effort spanning industry, state, the public sector, and citizenry...

Author: By Thomas J. Hwang | Title: To Be or not TB | 4/28/2010 | See Source »

...governments shoulder part of the blame and bear hope for progress. As students, we must stand up to ensure that drugs and essential technologies created and licensed at Harvard are made openly available. As citizens, we have a right to demand that our government understands that the eradication of TB is more than a charitable cause: It is a national-security, economic-policy, public-health, and moral issue. Finally, as human beings, we have an obligation to open our eyes to the many forgotten faces of suffering and poverty, some of whom are among us today, ravaged by the continued...

Author: By Thomas J. Hwang | Title: To Be or not TB | 4/28/2010 | See Source »

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next